Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

被引:88
作者
Gerber, Hans-Peter [1 ]
Wu, Xiumin [1 ]
Yu, Lanlan [1 ]
Wiesmann, Christian [1 ]
Liang, Xiao Huan [1 ]
Lee, Chingwei V. [1 ]
Fuh, Germaine [1 ]
Olsson, Christine [1 ]
Damico, Lisa [1 ]
Xie, David [1 ]
Meng, Y. Gloria [1 ]
Gutierrez, Johnny [1 ]
Corpuz, Racquel [1 ]
Li, Bing [1 ]
Hall, Linda [1 ]
Rangell, Linda [1 ]
Ferrando, Ron [1 ]
Lowman, Henry [1 ]
Peale, Franklin [1 ]
Ferrara, Napoleone [1 ]
机构
[1] Genentech Inc, San Francisco, CA 94080 USA
关键词
angiogenesis; gene knockin; tumor;
D O I
10.1073/pnas.0611492104
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
VEGF-A is important in tumor angiogenesis, and a humanized anti-VEGF-A monoclonal antibody (bevacizumab) has been approved by the FDA as a treatment for metastatic colorectal and nonsquamous, non-small-cell lung cancer in combination with chemotherapy. However, contributions of both tumor- and stromal-cell derived VEGF-A to vascularization of human tumors grown in immunodeficient mice hindered direct comparison between the pharmacological effects of anti-VEGF antibodies with different abilities to block host VEGF. Therefore, by gene replacement technology, we engineered mice to express a humanized form of VEGF-A (hum-X VEGF) that is recognized by many anti-VEGF antibodies and has biochemical and biological properties comparable with WT mouse and human VEGF-A. The hum-X VEGF mouse model was then used to compare the activity and safety of a panel of VEGF Mabs with different affinities for VEGF-A. Although in vitro studies clearly showed a correlation between binding affinity and potency at blocking endothelial cell proliferation stimulated by VEGF, in vivo experiments failed to document any consistent correlation between antibody affinity and the ability to inhibit tumor growth and angiogenesis in most animal models. However, higher-affinity antibodies were more likely to result in glomerulosclerosis during long-term treatment.
引用
收藏
页码:3478 / 3483
页数:6
相关论文
共 42 条
[1]   The role of antibody concentration and avidity in antiviral protection [J].
Bachmann, MF ;
Kalinke, U ;
Althage, A ;
Freer, G ;
Burkhart, C ;
Roost, HP ;
Aguet, M ;
Hengartner, H ;
Zinkernagel, RM .
SCIENCE, 1997, 276 (5321) :2024-2027
[2]   Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling [J].
Baffert, F ;
Le, T ;
Sennino, B ;
Thurston, G ;
Kuo, CJ ;
Hu-Lowe, D ;
McDonald, DM .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 290 (02) :H547-H559
[3]   Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways [J].
Baluk, P ;
Lee, CG ;
Link, H ;
Ator, E ;
Haskell, A ;
Elias, JA ;
McDonald, DM .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (04) :1071-1085
[4]   Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].
Bergers, G ;
Song, S ;
Meyer-Morse, N ;
Bergsland, E ;
Hanahan, D .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295
[5]   Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors [J].
Casanovas, O ;
Hicklin, DJ ;
Bergers, G ;
Hanahan, D .
CANCER CELL, 2005, 8 (04) :299-309
[6]   Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen [J].
Chen, Y ;
Wiesmann, C ;
Fuh, G ;
Li, B ;
Christinger, HW ;
McKay, P ;
de Vos, AM ;
Lowman, HB .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (04) :865-881
[8]   Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J].
Ferrara, N ;
Hillan, KJ ;
Gerber, HP ;
Novotny, W .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :391-400
[9]   Vascular endothelial growth factor: Basic science and clinical progress [J].
Ferrara, N .
ENDOCRINE REVIEWS, 2004, 25 (04) :581-611
[10]   Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J].
Ferrara, N ;
CarverMoore, K ;
Chen, H ;
Dowd, M ;
Lu, L ;
OShea, KS ;
PowellBraxton, L ;
Hillan, KJ ;
Moore, MW .
NATURE, 1996, 380 (6573) :439-442